Telix Pharmaceuticals (TLX) began trading on the Nasdaq on Thur 14 Nov 24

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. 

• Sector: Healthcare
• Industry: Biotechnology
• Founded by Andreas Kluge and Christian P. Behrenbruch in 2015 
• Headquartered in Melbourne, Australia
• https://telixpharma.com

TLX

Company Overview

A commercial-stage Australian biopharmaceutical company building a vertically integrated theranostics franchise across prostate cancer, renal cell carcinoma, and neuro-oncology through FDA-approved PSMA imaging agents and an advancing radiotherapeutic pipeline. Telix trades on both the ASX and NASDAQ under TLX, a dual listing that reflects its ambition to be judged against the global radiopharmaceutical field rather than merely the local market. With FY2025 revenue of US$803.8 million — up 56% year-over-year — Telix is firmly commercial, scaling its top line while reinvesting heavily in its therapeutic pipeline.

Headquarters and Global Presence

Telix is headquartered in Melbourne, Australia, with significant operations in the United States, Belgium, Switzerland, and Japan. Its US footprint expanded materially with the January 2025 acquisition of RLS Radiopharmacies, adding a domestic manufacturing and distribution network critical to radiopharmaceutical logistics.

Founding and History

Founded in 2015 by Dr Christian Behrenbruch and Dr Andreas Kluge, the company completed its initial public offering and ASX listing in November 2017 and added a NASDAQ listing in 2024 to broaden its investor base. The pivotal inflection came in 2021 when the FDA approved Illuccix, Telix's PSMA-PET imaging agent for prostate cancer, converting it from a development-stage entity into a revenue-generating business. Since then it has executed a series of strategic acquisitions — RLS Radiopharmacies, ImaginAb, Optimal Tracers, ARTMS, and IsoTherapeutics — to build vertical integration across the radiopharmaceutical value chain.

Therapy Areas and Focus

Telix's commercial and clinical centre of gravity is urologic cancers (prostate and kidney) and neuro-oncology (glioma), disease areas where tumor-targeting radiopharmaceuticals have a biological rationale and a growing clinical evidence base. Prostate cancer remains the commercial anchor, with PSMA as the dominant imaging target. Kidney and brain cancers represent the next waves — both carry significant unmet need, particularly in the metastatic and recurrent settings where current systemic therapies offer limited durability. Beyond these, Telix lists hematologic cancers as a core disease area — its TLX66 (CD66-targeting) program for bone marrow conditioning ahead of stem cell transplantation holds FDA and EU orphan-drug designations — and it is developing TLX300 in musculoskeletal (soft-tissue sarcoma) oncology.